Please Wait a Moment
X

Articles

10Jul

FDA Guidance for Industry for Babesia

10 Jul, 2019 | Return|

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.

 

Check out the Communication page for the complete details by clicking the link: Communications

Related

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...

Read More >

New Learning Center with New Content Launches on March 30!

A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...

Read More >

Procedure for pouring off samples if shipments will be extremely delayed

As winter weather continues to move through parts of the US, we would like to remind you it may be n...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

This is the first update to the original CTS communication distributed on July 6th. As previously co...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

Sample submission during the national blood shortage

Through communications with our clients, CTS is aware of the current national blood shortage. We rea...

Read More >